Level Biotechnology Inc (3118) Fair Value & Analysis
Healthcare · TW · Market cap 1.0B TWD
Fair value as of: Jul 21, 2026
From 22 valuation models · updated 20 days ago
Share price +0.9% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (25.25 TWD to 45.93 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 23.57 TWD – 37.15 TWD · fair‑value band 25.25 TWD – 45.93 TWD · the 32.00 TWD price screens below the 32.95 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Level Biotechnology Inc (3118) currently trades at 32.00 TWD, while our model-based Fair Value estimate is 32.95 TWD, implying the stock looks roughly 3.0% fairly valued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Level Biotechnology Inc generated revenue of 719M TWD at a net margin of 10.7%. Revenue declined 10.2% year over year. It earns a return on equity of 13.1%. The balance sheet holds a net cash position of 454M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 25.25 TWD (bear case) to 45.93 TWD (bull case); at 32.00 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 3%, 3118 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Multiples (41.75 TWD) versus Asset-Based (11.98 TWD). Highest evidence: Residual Income (76).
Notify me when 3118 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production.
Full company description
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Level Biotechnology Inc reported revenue of 737M TWD in FY2025 versus 677M TWD in FY2021, a compound +2.1%/yr. Reported net income was 79.7M TWD in FY2025, compounding +4.0%/yr from FY2021.
Watch 3118: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Level Biotechnology Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Level Biotechnology Inc (3118) overvalued or undervalued?
What is the fair value of 3118?
What is the quality score of 3118?
What is the revenue of Level Biotechnology Inc (3118)?
What is the net profit margin of 3118?
Does Level Biotechnology Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Level Biotechnology Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.